-
National Medical Insurance Administration: The cost of the new crown vaccine is within the affordable range of the medical insurance fund
Time of Update: 2022-04-19
Recently, the person in charge of the relevant department of the National Medical Insurance Bureau was interviewed by reporters on issues such as the price of the new coronavirus vaccine and the impact of purchasing the vaccine on the medical insurance fund, which are generally concerned by the society .
-
The pharmaceutical and biological industry is favored by institutions, and Puluo Pharmaceuticals, Mindray Medical, etc. are frequently investigated
Time of Update: 2022-04-19
In the institutional survey on March 17, Changchun High-tech stated that "the long-acting water injection has now begun to adjust the product price, and after the adjustment, more patients can enjoy the preferential price similar to the previous related public welfare activities .
-
Longeveron shares soar 105% after Phase I results of new Alzheimer's drug
Time of Update: 2022-04-19
Based on the findings, Longeveron opened a new, larger, double-blind, randomized, placebo-controlled Phase II study to evaluate the effects of single and multiple doses of Lomecel-B in the treatment of mild AD .
-
Domestic inhalation products are accelerating the market, and the market pattern may change
Time of Update: 2022-04-19
The industry believes that the continuous listing of inhalation preparations is mainly due to the continuous expansion of the domestic inhalation market in recent years with the increase in the incidence of respiratory diseases in my country, and pharmaceutical companies are scrambling to deploy in this field.
-
Heyu Pharma's Oral PD-L1 Inhibitor Obtained Clinical Approval
Time of Update: 2022-04-19
On March 30, the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that the ABSK043 capsules declared by Heyu Pharmaceutical obtained the implied license for clinical trials, and the proposed indication is malignant tumors .
-
The "14th Five-Year" Chinese medicine development plan deploys ten key tasks, and the industry development will usher in qualitative changes
Time of Update: 2022-04-19
Analysts said that the introduction of the "14th Five-Year Plan" for traditional Chinese medicine will promote the development of the industry and usher in a qualitative change .
-
National Medical Insurance Bureau: 23.4 billion yuan of medical insurance funds will be recovered in 2021
Time of Update: 2022-04-19
health health medicines medicines medicines_ In addition, the meeting emphasized that it is necessary to deeply and accurately grasp the complex situation facing the current fund supervision, focusing on tampering with inspection results, interchanging high-value medical consumables and other behaviors, always maintaining a high-pressure situation, strengthening coordination and linkage, strengthening overall guidance, comprehensively compacting responsibilities, and continuing to Strengthen capacity building, and continue to deepen the fight against fraud and insurance fraud with a "zero tolerance" attitude .
-
Huahai Pharmaceutical's impact on $1 billion variety of anti-gout drugs can be sold in the United States
Time of Update: 2022-04-18
On April 1, Huahai Pharmaceutical announced that the ANDA of levetiracetam injection and febuxostat tablets declared by the company to the FDA had been approved.
On April 1, Huahai Pharmaceutical announced that the ANDA of levetiracetam injection and febuxostat tablets declared by the company to the FDA had been approved.
-
The children's drug market is continuously favored by the policy, and the 100 billion market will explode
Time of Update: 2022-04-18
In order to solve the shortage of children's medicines, in recent years, the State Food and Drug Administration, the National Health Commission, the National Medical Insurance Administration and other departments have successively introduced a number of policies and measures to encourage the development and production of children's medicines .
-
In 2022, the "break" of innovative pharmaceutical companies will continue!
Time of Update: 2022-04-18
In January, Asieris Pharmaceuticals broke through at the opening of the market and became the first biopharmaceutical stock on the Science and Technology Innovation Board this year .
js ?cdnversion='+~(-new Date()/36e5)]; Keywords: In 2022, innovative pharmaceutical companies will continue to "break"!
-
Although the road for Chinese innovative drugs to go overseas is difficult, there are also new expectations...
Time of Update: 2022-04-18
The industry believes that the acceptance of this model by European companies means that the clinical and market value of the product has been recognized, which will help to accelerate the internationalization of Yifan Pharmaceuticals, and also provide some confidence and expectations for China's innovative drugs to go overseas .
-
Traditional Chinese medicine companies are attacking innovative drugs, and a large number of new drugs are already on the way
Time of Update: 2022-04-18
With the support of a series of favorable policies, pharmaceutical companies are enthusiastic about the innovation of traditional Chinese medicine, and they are also becoming more and more active in the application of traditional Chinese medicine registration .
-
Pay attention to the fast-growing sector in the first quarterly report. Yesterday, many pharmaceutical companies disclosed that their performance increased by more than double
Time of Update: 2022-04-18
According to the forecast, Canaan Technology expects that the net profit attributable to the first quarter of 2022 will increase by 50% to 80% year-on-year, about 16.
-
The pharmaceutical industry is booming, and a group of pharmaceutical executives have earned more than $10 million
Time of Update: 2022-04-18
The overall performance of multinational pharmaceutical companies recovered last year, so the salary of most executives has increased .
For example, the salaries of CEOs of Roche and Novartis, two multinational pharmaceutical companies, will increase in 2021 .
-
A number of innovative drug companies have achieved outstanding commercialization performance, and sales revenue has grown strongly!
Time of Update: 2022-04-18
It is reported that due to the continuous growth of research and development expenses, Junshi Bio's operating income cannot cover the growing research and development expenses and other expenses, resulting in the company not yet achieving profitability in 2021 .
-
Multinational pharmaceutical companies are intensively adjusting their structures, and merging production lines is becoming the norm
Time of Update: 2022-04-17
Recently, it has been reported that Takeda Pharmaceutical China will merge the product lines of pantoprazole sodium enteric-coated tablets and vonora fumarate green tablets .
Affected by this, the merger of product lines of domestic multinational pharmaceutical companies may become more and more common in the future .
-
Nanjing Chia Tai Tianqing to win $1.5 billion extended-release tablets
Time of Update: 2022-04-17
Recently, Nanjing Chia Tai Tianqing entered the administrative approval stage with Mirabegron extended-release tablets, which are imitated Category 4, and is expected to be approved for marketing in the near future .
-
PI3Kδ inhibitor leniolisib meets primary endpoint of pivotal clinical trial
Time of Update: 2022-04-17
A few days ago, Pharming announced the latest data from the pivotal Phase 2/3 clinical trial of the PI3Kδ inhibitor leniolisib in patients with PI3Kδ activation syndrome .
-
In March, a large number of senior executives of pharmaceutical companies left, including more than 8 deputy general managers
Time of Update: 2022-04-17
On March 30, Hualan Bio announced that the company's executives had undergone personnel changes, saying that three deputy general managers had resigned .
On March 7, Doray Pharmaceuticals issued an announcement that the company's board of directors recently received a written resignation report submitted by the company's deputy general manager, Mr.
-
The listing application of Huiyu Pharmaceutical's Class 4 generic drug Octreotide Acetate Injection has entered the stage of administrative approval
Time of Update: 2022-04-17
com, the terminal sales of this product in China's public medical institutions will exceed 2 billion yuan in 2020.
Application of Consistency Evaluation of Octreotide Acetate Injection (including new classification report) Source: Minet.
